Biogen

4Q Revenues: $2.8 billion (+8%)

4Q Earnings: $828.7 million (-6%)

FY Revenues: $10.8 billion (+11%)

FY Earnings: $3.5 billion (+21%)

Comments: TECFIDERA revenues were $3.6 billion for the year, up 24%, with $2.9 billion in U.S. sales and $730 million in sales outside the U.S. Interferon revenues, including AVONEX and PLEGRIDY, were $3.0 billion, down 3%, with $2.0 billion in U.S. sales and $951 million in sales outside the U.S. TYSABRIrevenues were $1.9 billion, down 5%, with $1.1 billion in U.S. sales and $783 million in sales outside the U.S. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $1.3 billion, up 8%. Royalty revenues were $48 million compared to $177 million in 2014.